PMC:3724972 / 22464-23003 JSONTXT

{"project":"2_test","denotations":[{"id":"23673515-20972839-63233661","span":{"begin":171,"end":173},"obj":"20972839"},{"id":"23673515-22584716-63233662","span":{"begin":175,"end":177},"obj":"22584716"},{"id":"23673515-20668043-63233663","span":{"begin":321,"end":323},"obj":"20668043"},{"id":"23673515-20870708-63233663","span":{"begin":321,"end":323},"obj":"20870708"},{"id":"23673515-20660056-63233663","span":{"begin":321,"end":323},"obj":"20660056"},{"id":"23673515-20972839-63233664","span":{"begin":523,"end":525},"obj":"20972839"},{"id":"23673515-20668043-63233665","span":{"begin":527,"end":529},"obj":"20668043"},{"id":"23673515-20660056-63233666","span":{"begin":531,"end":533},"obj":"20660056"},{"id":"23673515-17926052-63233667","span":{"begin":535,"end":537},"obj":"17926052"}],"text":"To date, ~30 cases of pituitary adenoma have been treated with temozolomide (including ten ACTH-secreting adenomas). Overall reported response rate is approximately 60 % [62, 63]; however, information on temozolomide treatment of pituitary adenomas is currently confined to individual case reports and three case series [65–67]. An inverse relationship between tumoral O6-methylguanine-DNA methyltransferase (MGMT) immunoexpression and response to temozolomide therapy has been suggested, but not confirmed in all studies [62, 65, 67, 68]."}